Is Lantern Pharma Inc (LTRN) overvalued? · $35.1M cap
Lantern Pharma Inc (LTRN) is a biotechnology company listed on US.
This page asks whether Lantern Pharma Inc (LTRN) looks expensive on cached numbers — not a short thesis.
No cached income statement for LTRN, so there is no earnings base to call rich or cheap.
LTRN currently screens at market cap $35.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LTRN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LTRN stock page for the full model, not this heading.
Not investment advice.